Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease
Identifieur interne : 004562 ( Main/Curation ); précédent : 004561; suivant : 004563Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease
Auteurs : David J. Burn [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Antidepressant agent, Antidepressive Agents (therapeutic use), Antidepressive Agents, Second-Generation (therapeutic use), Antidepressive Agents, Tricyclic (therapeutic use), Brain (metabolism), Chemotherapy, Depression, Depressive Disorder (diagnosis), Depressive Disorder (drug therapy), Depressive Disorder (etiology), Depressive Disorder (psychology), Diagnosis, Human, Humans, Parkinson Disease (complications), Parkinson Disease (metabolism), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Psychiatric Status Rating Scales, Quality of Life, Reuptake inhibitor, Review, Serotonin, Serotonin Uptake Inhibitors (therapeutic use), Treatment, Treatment Outcome, Tricyclic compound, aetiology, clinical features, depression, treatment.
- MESH :
- chemical , therapeutic use : Antidepressive Agents, Antidepressive Agents, Second-Generation, Antidepressive Agents, Tricyclic, Serotonin Uptake Inhibitors.
- complications : Parkinson Disease.
- diagnosis : Depressive Disorder.
- drug therapy : Depressive Disorder.
- etiology : Depressive Disorder.
- metabolism : Brain, Parkinson Disease.
- psychology : Depressive Disorder, Parkinson Disease.
- Humans, Psychiatric Status Rating Scales, Quality of Life, Treatment Outcome.
Abstract
This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery‐Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM‐IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo‐controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10114
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000003
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000003
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002E54
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003A68
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003A68
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003B84
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000783
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000783
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000783
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006568
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002742
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000579
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002850
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006889
Links to Exploration step
ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10114</idno>
<idno type="url">https://api.istex.fr/document/5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000003</idno>
<idno type="wicri:Area/Istex/Curation">000003</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E54</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12112190</idno>
<idno type="wicri:Area/PubMed/Corpus">003A68</idno>
<idno type="wicri:Area/PubMed/Curation">003A68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B84</idno>
<idno type="wicri:Area/Ncbi/Merge">000783</idno>
<idno type="wicri:Area/Ncbi/Curation">000783</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000783</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:Area/Main/Merge">006568</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0368513</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002742</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000579</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002850</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:Area/Main/Merge">006889</idno>
<idno type="wicri:Area/Main/Curation">004562</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Consultant and Senior Lecturer in Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-05">2002-05</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="445">445</biblScope>
<biblScope unit="page" to="454">454</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<idno type="DOI">10.1002/mds.10114</idno>
<idno type="ArticleID">MDS10114</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antidepressive Agents, Second-Generation (therapeutic use)</term>
<term>Antidepressive Agents, Tricyclic (therapeutic use)</term>
<term>Brain (metabolism)</term>
<term>Chemotherapy</term>
<term>Depression</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Depressive Disorder (etiology)</term>
<term>Depressive Disorder (psychology)</term>
<term>Diagnosis</term>
<term>Human</term>
<term>Humans</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Reuptake inhibitor</term>
<term>Review</term>
<term>Serotonin</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>Tricyclic compound</term>
<term>aetiology</term>
<term>clinical features</term>
<term>depression</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
<term>Antidepressive Agents, Second-Generation</term>
<term>Antidepressive Agents, Tricyclic</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antidépresseur</term>
<term>Article synthèse</term>
<term>Chimiothérapie</term>
<term>Composé tricyclique</term>
<term>Diagnostic</term>
<term>Etat dépressif</term>
<term>Homme</term>
<term>Inhibiteur recapture</term>
<term>Parkinson maladie</term>
<term>Sérotonine</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery‐Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM‐IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo‐controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2002:Burn D:beyond:the:iron"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0368513</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0368513 INIST</idno>
<idno type="RBID">Pascal:02-0368513</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002742</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000579</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002850</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:Area/Main/Merge">006889</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne</s1>
<s2>Newcastle upon Tyne</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term>
<term>Chemotherapy</term>
<term>Depression</term>
<term>Diagnosis</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Reuptake inhibitor</term>
<term>Review</term>
<term>Serotonin</term>
<term>Treatment</term>
<term>Tricyclic compound</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Etat dépressif</term>
<term>Antidépresseur</term>
<term>Composé tricyclique</term>
<term>Chimiothérapie</term>
<term>Inhibiteur recapture</term>
<term>Sérotonine</term>
<term>Article synthèse</term>
<term>Diagnostic</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery-Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM-IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo-controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10114</idno>
<idno type="url">https://api.istex.fr/document/5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000003</idno>
<idno type="wicri:Area/Istex/Curation">000003</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E54</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12112190</idno>
<idno type="wicri:Area/PubMed/Corpus">003A68</idno>
<idno type="wicri:Area/PubMed/Curation">003A68</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B84</idno>
<idno type="wicri:Area/Ncbi/Merge">000783</idno>
<idno type="wicri:Area/Ncbi/Curation">000783</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000783</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Burn D:beyond:the:iron</idno>
<idno type="wicri:Area/Main/Merge">006568</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Consultant and Senior Lecturer in Neurology, Regional Neurosciences Centre, Newcastle General Hospital, and University of Newcastle upon Tyne, Newcastle upon Tyne</wicri:regionArea>
<wicri:noRegion>Newcastle upon Tyne</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-05">2002-05</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="445">445</biblScope>
<biblScope unit="page" to="454">454</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B</idno>
<idno type="DOI">10.1002/mds.10114</idno>
<idno type="ArticleID">MDS10114</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressive Agents (therapeutic use)</term>
<term>Antidepressive Agents, Second-Generation (therapeutic use)</term>
<term>Antidepressive Agents, Tricyclic (therapeutic use)</term>
<term>Brain (metabolism)</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Depressive Disorder (etiology)</term>
<term>Depressive Disorder (psychology)</term>
<term>Humans</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson's disease</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Treatment Outcome</term>
<term>aetiology</term>
<term>clinical features</term>
<term>depression</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
<term>Antidepressive Agents, Second-Generation</term>
<term>Antidepressive Agents, Tricyclic</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Psychiatric Status Rating Scales</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This review examines the frequency of depression complicating Parkinson's disease (PD), its aetiology and clinical features, and also how it may be recognised and treated. Studies investigating the frequency of depression in PD have yielded figures ranging between 2.7% and 70%. Methodological differences account for much of the disparity. The aetiology of depression in PD is complex, and probably relates to both biological and exogenous factors. Dysfunction of multiple neurotransmitter systems, including the serotonergic system, may be involved. Mood disturbances resulting from deep brain stimulation of the subthalamic nucleus may provide a fruitful area for future research, and assist our understanding of the neural networks involved in mediating depression. Several recent studies have confirmed that depression in the PD patient is a major determinant of quality of life and that this is closely related to dysfunction in other clinically important health areas. The validity for many existing scales in the screening, diagnosis, and monitoring of depression in the PD patient has not been established. The Montgomery‐Åsberg Depression Rating Scale and the Hamilton Rating Scale for Depression appear to have good diagnostic sensitivity and specificity when compared with DSM‐IV criteria. Recommendations for the optimal drug treatment of depression in PD are difficult to give, due to an inexplicable dearth of sizeable, placebo‐controlled studies. A majority of physicians would probably now opt for a selective serotonin reuptake inhibitor in the depressed PD patient. There is no good evidence that these drugs are associated with a worsening of motor features, but they should probably not be coprescribed with selegiline, because of the risk of causing a potentially serious serotonin syndrome. Several studies have suggested that depression in the PD patient is associated with a more rapid deterioration in cognitive and motor functions, perhaps as a surrogate marker for more extensive brainstem cell loss. © 2002 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:5DBBDE16B41926CCD7D766FA7F1B8832F1297D5B |texte= Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |